Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-Line Chemotherapy and Trastuzumab With or Without Bevacizumab for HER-2/NEU Over-Expressing Metastatic Breast Cancer
NCT00520975Phase 3Terminated
- Sponsor
- National Cancer Institute
- Start
- Nov 2007
- Primary completion
- Oct 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab in breast cancer, sponsored by National Cancer Institute. Started Nov 2007; status: terminated.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00520975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00520975.